ArticleOncology letters2025
Charged multivesicular body protein 4C promotes the progression of cervical cancer through the HPV E6/miR‑543 axis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Charged multivesicular body protein 4C (CHMP4C), as a subunit of endosomal sorting complex required for transport-III, is important for the abscission checkpoint in cell division, preventing premature cell division and genetic damage. The present study aimed to assess the role of CHMP4C in cervical cancer and the associated mechanisms. The levels of CHMP4C in normal and cervical cancer tissues were detected by immunohistochemistry. The MTT assay, apoptosis, wound-healing assay, and cell invasion assay were performed. Western blotting was performed to analyze the level of cancer-related proteins following CHMP4C downregulation and the CHMP4C expression following E6 downregulation and miR-543 upregulation. The transfection effectiveness of siRNA, plasmid, and miRNA mimic as well as the expression of miR-543 after silencing E6 were assessed by RT-PCR. The dual-luciferase reporter assay was used to demonstrate a connection site between CHMP4C and miR-543. The results demonstrated that CHMP4C expression in cervical cancer tissues was significantly higher than that in normal tissues. Furthermore, downregulation of CHMP4C expression significantly reduced the proliferation, migration and invasion of cervical cancer cells and significantly increased the rate of apoptosis compared to the si-scramble group. Comparison with the si-scramble group, silencing CHMP4C expression also significantly reduced the expression of Bcl2, Bcl-xL and Survivin, and was associated with a significant increase in Caspase-7 expression. After the knockdown of human papillomavirus (HPV)-encoded E6, in comparison to the si-scramble group, microRNA (miR)-543 expression was significantly elevated and CHMP4C expression significantly decreased. Moreover, a connection site was detected between miR-543 and CHMP4C. These findings indicate that CHMP4C accelerates the tumorigenesis and progression of cervical cancer through the HPV E6/miR-543 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.